US20110038933A1 - Stable benzimidazole formulation - Google Patents
Stable benzimidazole formulation Download PDFInfo
- Publication number
- US20110038933A1 US20110038933A1 US12/866,255 US86625509A US2011038933A1 US 20110038933 A1 US20110038933 A1 US 20110038933A1 US 86625509 A US86625509 A US 86625509A US 2011038933 A1 US2011038933 A1 US 2011038933A1
- Authority
- US
- United States
- Prior art keywords
- composition
- substrate
- coating layer
- group
- benzimidazole derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 135
- 238000009472 formulation Methods 0.000 title abstract description 27
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 title abstract description 10
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 55
- 239000013557 residual solvent Substances 0.000 claims abstract description 7
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims description 55
- 229960000381 omeprazole Drugs 0.000 claims description 54
- 239000000758 substrate Substances 0.000 claims description 54
- 150000001556 benzimidazoles Chemical class 0.000 claims description 45
- 239000002702 enteric coating Substances 0.000 claims description 40
- 238000009505 enteric coating Methods 0.000 claims description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 35
- 229920000642 polymer Polymers 0.000 claims description 34
- 239000011247 coating layer Substances 0.000 claims description 31
- 239000000243 solution Substances 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 29
- 238000000576 coating method Methods 0.000 claims description 28
- 239000010410 layer Substances 0.000 claims description 28
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 27
- 230000003113 alkalizing effect Effects 0.000 claims description 27
- 239000011248 coating agent Substances 0.000 claims description 24
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 22
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 18
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims description 16
- -1 mantitol Chemical compound 0.000 claims description 16
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 14
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 14
- 239000003960 organic solvent Substances 0.000 claims description 13
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 12
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 12
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 12
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 10
- 125000005263 alkylenediamine group Chemical group 0.000 claims description 10
- 150000001414 amino alcohols Chemical class 0.000 claims description 10
- 229910021529 ammonia Inorganic materials 0.000 claims description 10
- 239000004475 Arginine Substances 0.000 claims description 9
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 9
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 9
- 239000004472 Lysine Substances 0.000 claims description 9
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 9
- 229920002845 Poly(methacrylic acid) Polymers 0.000 claims description 9
- 229920002472 Starch Polymers 0.000 claims description 9
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 9
- 239000008188 pellet Substances 0.000 claims description 9
- 229940032147 starch Drugs 0.000 claims description 9
- 239000008107 starch Substances 0.000 claims description 9
- 235000019698 starch Nutrition 0.000 claims description 9
- 239000000454 talc Substances 0.000 claims description 9
- 229910052623 talc Inorganic materials 0.000 claims description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 8
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 8
- 230000007935 neutral effect Effects 0.000 claims description 7
- 239000011734 sodium Substances 0.000 claims description 7
- 229910052708 sodium Inorganic materials 0.000 claims description 7
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 6
- 229920003134 Eudragit® polymer Polymers 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
- 229920002301 cellulose acetate Polymers 0.000 claims description 6
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 6
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- XMYQHJDBLRZMLW-UHFFFAOYSA-N methanolamine Chemical compound NCO XMYQHJDBLRZMLW-UHFFFAOYSA-N 0.000 claims description 6
- 229940087646 methanolamine Drugs 0.000 claims description 6
- 230000003472 neutralizing effect Effects 0.000 claims description 6
- 239000004408 titanium dioxide Substances 0.000 claims description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 5
- 239000000908 ammonium hydroxide Substances 0.000 claims description 5
- 239000007884 disintegrant Substances 0.000 claims description 5
- 239000000945 filler Substances 0.000 claims description 5
- 239000000314 lubricant Substances 0.000 claims description 5
- 239000004014 plasticizer Substances 0.000 claims description 5
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 claims description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 claims description 4
- 239000011324 bead Substances 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- 239000003086 colorant Substances 0.000 claims description 4
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 229960003174 lansoprazole Drugs 0.000 claims description 4
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 claims description 4
- 229960005019 pantoprazole Drugs 0.000 claims description 4
- 238000005453 pelletization Methods 0.000 claims description 4
- 238000005498 polishing Methods 0.000 claims description 4
- 239000008109 sodium starch glycolate Substances 0.000 claims description 4
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 4
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 4
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 3
- PSIREIZGKQBEEO-UHFFFAOYSA-N 2-(1h-benzimidazol-2-ylsulfinylmethyl)-n-methyl-n-(2-methylpropyl)aniline Chemical compound CC(C)CN(C)C1=CC=CC=C1CS(=O)C1=NC2=CC=CC=C2N1 PSIREIZGKQBEEO-UHFFFAOYSA-N 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 235000019739 Dicalciumphosphate Nutrition 0.000 claims description 3
- 239000004386 Erythritol Substances 0.000 claims description 3
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 3
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000001856 Ethyl cellulose Substances 0.000 claims description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 3
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 3
- 229920003138 Eudragit® L 30 D-55 Polymers 0.000 claims description 3
- 239000005715 Fructose Substances 0.000 claims description 3
- 229930091371 Fructose Natural products 0.000 claims description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 229920001908 Hydrogenated starch hydrolysate Polymers 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 229920000881 Modified starch Polymers 0.000 claims description 3
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 claims description 3
- 108010009736 Protein Hydrolysates Proteins 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical class [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- 235000010443 alginic acid Nutrition 0.000 claims description 3
- 229920000615 alginic acid Polymers 0.000 claims description 3
- 239000000783 alginic acid Substances 0.000 claims description 3
- 229960001126 alginic acid Drugs 0.000 claims description 3
- 150000004781 alginic acids Chemical class 0.000 claims description 3
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 239000001506 calcium phosphate Substances 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- 229940105329 carboxymethylcellulose Drugs 0.000 claims description 3
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 claims description 3
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 claims description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 3
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 claims description 3
- 229940038472 dicalcium phosphate Drugs 0.000 claims description 3
- 229910000390 dicalcium phosphate Inorganic materials 0.000 claims description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 3
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 3
- 235000019800 disodium phosphate Nutrition 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- 235000019414 erythritol Nutrition 0.000 claims description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 3
- 229940009714 erythritol Drugs 0.000 claims description 3
- KWORUUGOSLYAGD-YPPDDXJESA-N esomeprazole magnesium Chemical compound [Mg+2].C([S@](=O)C=1[N-]C2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C.C([S@](=O)C=1[N-]C2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C KWORUUGOSLYAGD-YPPDDXJESA-N 0.000 claims description 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 3
- 229920001249 ethyl cellulose Polymers 0.000 claims description 3
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 239000000905 isomalt Substances 0.000 claims description 3
- 235000010439 isomalt Nutrition 0.000 claims description 3
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims description 3
- 239000000832 lactitol Substances 0.000 claims description 3
- 235000010448 lactitol Nutrition 0.000 claims description 3
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 3
- 229960003451 lactitol Drugs 0.000 claims description 3
- 229950007395 leminoprazole Drugs 0.000 claims description 3
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 229960003194 meglumine Drugs 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- RTWNYYOXLSILQN-UHFFFAOYSA-N methanediamine Chemical compound NCN RTWNYYOXLSILQN-UHFFFAOYSA-N 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- XNGIFLGASWRNHJ-UHFFFAOYSA-N o-dicarboxybenzene Natural products OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 claims description 3
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229940068968 polysorbate 80 Drugs 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- AOHJOMMDDJHIJH-UHFFFAOYSA-N propylenediamine Chemical compound CC(N)CN AOHJOMMDDJHIJH-UHFFFAOYSA-N 0.000 claims description 3
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 claims description 3
- 229960004157 rabeprazole Drugs 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 235000010413 sodium alginate Nutrition 0.000 claims description 3
- 239000000661 sodium alginate Substances 0.000 claims description 3
- 229940005550 sodium alginate Drugs 0.000 claims description 3
- 239000001488 sodium phosphate Substances 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 235000010356 sorbitol Nutrition 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 125000005591 trimellitate group Chemical group 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- 238000007906 compression Methods 0.000 claims description 2
- 230000006835 compression Effects 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 abstract description 10
- 238000003860 storage Methods 0.000 abstract description 7
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 3
- 239000003826 tablet Substances 0.000 description 44
- 239000000523 sample Substances 0.000 description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 230000002378 acidificating effect Effects 0.000 description 11
- 239000006185 dispersion Substances 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 238000011084 recovery Methods 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 238000009498 subcoating Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 239000011550 stock solution Substances 0.000 description 5
- 238000010998 test method Methods 0.000 description 5
- 239000001069 triethyl citrate Substances 0.000 description 5
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 5
- 235000013769 triethyl citrate Nutrition 0.000 description 5
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000007950 delayed release tablet Substances 0.000 description 4
- 238000007865 diluting Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 229920003136 Eudragit® L polymer Polymers 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 229960001375 lactose Drugs 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 3
- 238000012421 spiking Methods 0.000 description 3
- 239000012086 standard solution Substances 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- 229920006318 anionic polymer Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229920001688 coating polymer Polymers 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229940126409 proton pump inhibitor Drugs 0.000 description 2
- 239000000612 proton pump inhibitor Substances 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 101001126084 Homo sapiens Piwi-like protein 2 Proteins 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 102100029365 Piwi-like protein 2 Human genes 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- GYMWQLRSSDFGEQ-ADRAWKNSSA-N [(3e,8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 GYMWQLRSSDFGEQ-ADRAWKNSSA-N 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000002998 adhesive polymer Substances 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 239000012055 enteric layer Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 229940080350 sodium stearate Drugs 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000005563 spheronization Methods 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
Definitions
- the present invention relates to a novel stable formulation for an acid labile benzimidazole, and methods of preparation and administration thereof, and in particular, for a stable formulation of a benzimidazole which is suitable for oral administration, and has low levels of residual volatile excipients such as solvents.
- Omeprazole, Pantoprazole, Lansoprazole and other derivatives of benzimidazole, which are active proton pump inhibitors and used conventionally for decreasing gastric secretion are known to be susceptible to degradation and transformation in acid media.
- Omeprazole, 5-methoxy-2(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole is disclosed and described in European Patent No. 5129 and European Patent No. 124495, as well as in numerous other patents and published patent applications.
- Omeprazole degrades with a half-life of less than 10 minutes in an environment with pH values below 4.0. At pH 6.5, the half life of Omeprazole is 18 hours and at pH 11 about 300 days. Therefore, the environment of Omeprazole should be kept at a sufficiently high pH value in order to maintain the stability of the compound, in a formulation which is suitable as a product for oral administration, for example by locating Omeprazole within a core which also contains alkaline constituents. This leads to an alkaline reaction aimed at improving stability of the active substance during manufacture thereof and during storage of the pharmaceutical formulation.
- PCT Application No. WO 97/12581 discloses a composition adapted for oral administration containing Omeprazole which specifically does not include alkaline-reacting compounds. Instead, the composition features a core composed of a nuclei and Omeprazole compressed together, an intermediate layer and an enteric layer.
- European Patent Application No. 519,144 discloses a formulation for Omeprazole, which features a neutral (sugar) core. Omeprazole is sprayed onto the sugar core, after which an intermediate coating layer and an enteric coating layer are sprayed onto the core.
- PCT Application No. WO 98/00114 discloses a modification to other background art formulations for Omeprazole, in which the intermediate subcoating layer is partially neutralized with an alkaline compound.
- this modified formulation still features the subcoating layer, which is a disadvantage in that it complicates the manufacturing process and increases the expense and difficulty of manufacture.
- the formulation disclosed in PCT Application No. WO 98/00114 like those disclosed in European Patent Application No. 519,144 and other background art references, has the disadvantage of requiring the intermediate layer.
- WO 83/00435 discloses a solid dosage form, such as a capsule or tablet, containing a pharmacologically active agent coated with an anionic polymer, which is insoluble in gastric juice and in intestinal juice below pH 7.
- the preferred anionic polymer is a partly methyl esterified methacrylic acid polymer in which the ratio of free carboxylic groups to ester groups is about 1:2.
- Omeprazole is not disclosed as one of the active agents.
- French Application No. 2,692,146 discloses stable compositions of microgranules of gastro-protected Omeprazole.
- the composition features a center of Omeprazole diluted in mannitol. This center is coated with an intermediate layer featuring mannitol. An enteric coating is then added over this intermediate layer.
- PCT Application No. WO 97/12581 discloses a formulation in which an intermediate layer between the core and an enteric coating contains silicium dioxide.
- PCT Application No. WO 96/37195 discloses a formulation which lacks a subcoating layer, but which features a core containing titanium dioxide. Both the core containing Omeprazole and the enteric coating layer placed on top of the core include titanium dioxide as an ingredient. Unfortunately, titanium dioxide is only able to mask the discoloration caused by the reaction between Omeprazole and the enteric coating layer, but cannot prevent such an undesirable reaction. Thus, the disclosed formulation does not prevent the undesirable reaction between the benzimidazole derivative and the enteric coating, which is known in the art.
- German Patent Application No. 196 26 045 A1 discloses a method for stabilising Omeprazole by coating small tablets or pellets, containing large amounts of mannitol, with a subcoating of Eudragit L.
- the subcoating of Eudragit L is neutralized, after which a final enteric coat of non-neutralized Eudragit L is applied.
- a formulation of a benzimidazole derivative, such as Omeprazole, which lacks an intermediate coating layer and yet which is stable both during storage and during the passage through the stomach, is described in U.S. patent application Ser. No. 10/018,992.
- This formulation involves neutralization of the enteric coating with an alkaline compound, such as ammonium hydroxide.
- the formulation is simple to manufacture and exposes the sensitive benzimidazole derivative to fewer production steps, thereby decreasing degradation of the active compound during production.
- the background art does not teach or suggest a benzimidazole formulation, particularly for Omeprazole, which lacks an intermediate layer and yet which is stable both during storage and during the passage through the stomach, and which has low levels of residual alkalinizing agents and residual solvents.
- the present invention overcomes these drawbacks of the background art by providing a benzimidazole formulation which lacks an intermediate layer and yet which is stable both during storage and during the passage through the stomach, and which has low levels of residual volatile excipients, including but not limited to residual alkalinizing agents and/or residual solvents.
- a stable composition for a benzimidazole derivative comprising a substrate, comprising the benzimidazole derivative; and a single coating layer consisting essentially of at least one neutralized enteric polymer, the enteric polymer having been neutralized by an alkalizing agent.
- the alkalizing agent is selected from the group consisting of amino alcohols, alkylene diamines, ammonia solution, arginine and lysine.
- the composition comprises less than about 500 parts per million of residual alkalizing agent relative to the total weight of the composition.
- a stable composition for a benzimidazole derivative comprising a substrate comprising the benzimidazole derivative and a single coating layer consisting of one or more enteric polymers treated by at least one volatile alkalizing agent prior to applying over the substrate.
- the composition comprises less than 500 parts per million of residual volatile alkalizing agents relative to the composition weight, and a pH of the coating layer is in the range of from about 4.5 to about 6.5 as measured in 30 ml of distilled water at 20-25° C.
- the pH is in the range of from about 5 to about 6; more preferably the pH is about 5.
- the alkalizing agent comprises at least one of basic sodium, potassium, methanolamine, ammonium solution (such as ammonium hydroxide), amino alcohols (such as methanolamine, monoethanol amine, or propanolamine, or combinations thereof), arginine, lysine, and alkylene diamines (such as methylene diamine, ethylene diamine, or propylene diamine, or combinations thereof).
- the enteric polymer is dissolved in an organic solvent prior to application.
- such a composition comprises less than about 1000 parts per million of residual organic solvent.
- Non-limiting examples of organic solvents include acetone, ethanol, isopropanol or a mixture thereof.
- Non-limiting examples of enteric polymers include cellulose acetate phthalate (CAP); hydroxypropyl methylcellulose phthalate (HPMCP); polyvinyl acetate phthalate; cellulose acetate trimellitate; poly((methacrylic acid, methyl methacrylate)1:1) (Eudragit L100TM), poly((methacrylic acid, ethyl acrylate)1:1) (Eudragit L30D-55) or Eudragit L100-55TM, (poly(methacrylic acid, methyl methacrylate)1:2) EudragitTM S hydroxypropyl methylcellulose acetate succinate (HPMCAS), sodium alginate, and alginic acid or mixtures thereof.
- CAP cellulose acetate phthalate
- HPMCP hydroxypropyl methylcellulose phthalate
- HPP hydroxypropyl methylcellulose phthalate
- HPP hydroxypropyl methylcellulose phthalate
- HPP hydroxypropyl
- the substrate is an active core for containing the benzimidazole derivative, such as, for example, a pellet, a bead or a tablet.
- the active core is a tablet formed by compression.
- the substrate features a neutral core; and an active coating containing the benzimidazole derivative, wherein the active coating is layered over the neutral core; such that the composition is in a form of a pellet.
- the substrate features a core containing the benzimidazole derivative with a suitable binding agent, the core being prepared by spheronisation and pelletization; such that the composition is in a form of a pellet.
- the benzimidazole is optionally one or more of Omeprazole, Pantoprazole, Lansoprazole, Leminoprazole, Perprazole, Rabeprazole, or pharmaceutically acceptable salts thereof, or combinations thereof.
- the substrate further comprises a filler, such as, for example, one or more of microcrystalline cellulose, sodium carboxymethycellulose, ethylcellulose, cellulose acetate, starch, lactose, glucose, fructose, sucrose, dicalcium phosphate, sorbitol, mannitol, mantitol, lactitol, xylitol, isomalt, erythritol, and hydrogenated starch hydrolysates, or a mixture thereof.
- a filler such as, for example, one or more of microcrystalline cellulose, sodium carboxymethycellulose, ethylcellulose, cellulose acetate, starch, lactose, glucose, fructose, sucrose, dicalcium phosphate, sorbitol, mannitol, mantitol, lactitol, xylitol, isomalt, erythritol, and hydrogenated starch hydrolysates, or a
- the substrate further comprises a disintegrant, such as, for example, one or more of low-substituted carboxymethyl cellulose sodium, cross-linked polyvinyl pyrrolidone, sodium starch glycolate, cross-linked sodium carboxymethyl cellulose, pregelatinized starch, microcrystalline starch, water insoluble starch, calcium carboxymethyl cellulose, and low substituted hydroxypropyl cellulose magnesium aluminum silicate, or a mixture thereof.
- a disintegrant such as, for example, one or more of low-substituted carboxymethyl cellulose sodium, cross-linked polyvinyl pyrrolidone, sodium starch glycolate, cross-linked sodium carboxymethyl cellulose, pregelatinized starch, microcrystalline starch, water insoluble starch, calcium carboxymethyl cellulose, and low substituted hydroxypropyl cellulose magnesium aluminum silicate, or a mixture thereof.
- the substrate further comprises a lubricant, such as, for example, one or more of sodium stearyl fumarate, polyethylene glycol, silica colloidal anhydrous and magnesium stearate, or a mixture thereof.
- a lubricant such as, for example, one or more of sodium stearyl fumarate, polyethylene glycol, silica colloidal anhydrous and magnesium stearate, or a mixture thereof.
- the substrate further comprises an alkalinizing agent, such as, for example, one or more of sodium stearate, meglumine, disodium phosphate, and ammonia, or a mixture thereof.
- an alkalinizing agent such as, for example, one or more of sodium stearate, meglumine, disodium phosphate, and ammonia, or a mixture thereof.
- the coating layer further comprises a plasticizer, such as, for example, one or more of a citric acid ester and a phthalic acid ester.
- a plasticizer such as, for example, one or more of a citric acid ester and a phthalic acid ester.
- the coating layer further comprises a surfactant, such as, for example, one or more of polysorbate 80 and sodium lauryl sulfate.
- a surfactant such as, for example, one or more of polysorbate 80 and sodium lauryl sulfate.
- the coating layer further comprises a glidant, such as, for example one or more of talc and titanium dioxide.
- a glidant such as, for example one or more of talc and titanium dioxide.
- the coating layer further comprises at least one of a coloring agent and a polishing agent.
- a method for preparing a stable composition for a benzimidazole derivative comprising neutralizing one or more enteric polymers with at least one volatile alkalizing agent; and layering the enteric polymer(s) over a substrate comprising the benzimidazole derivative to form a coating layer, the composition comprising the substrate and the coating layer, such that the composition comprises less than 1000 parts per million of residual volatile alkalizing agents relative to composition weight.
- the alkalizing agent comprises one or more of amino alcohols, alkylene diamines, arginine, lysine, and ammonia solution.
- a method for preparing a stable composition for a benzimidazole derivative comprising dissolving one or more enteric polymers in an organic solvent; neutralizing the enteric polymer(s) with at least one volatile alkalizing agent; and layering the enteric polymer(s) over a substrate comprising the benzimidazole derivative to form a coating layer, the composition comprising the substrate and the coating layer, such that the composition comprises less than 1000 parts per million of residual solvent relative to composition weight.
- FIGS. 1-6 relate to the suitability of test method for determination of residual monoethanolamine.
- the formulation of the present invention contains a benzimidazole derivative, such as Omeprazole, and is able to maintain the stability of this active ingredient without a separating layer between the active compound and an enteric coating layer.
- the enteric coating layer is prepared as an aqueous dispersion or in organic solvent and neutralized with an alkalinizing agent, before being applied as a solution directly to the benzimidazole derivative substrate.
- the aqueous dispersion has a pH in the range of at least 6.5, and more preferably in the range of from about 7 to about 10.
- the aqueous dispersion After being applied to the substrate, the aqueous dispersion dries to form a coating layer, preferably having a pH in the range of from about 4.5 to about 6.5, and more preferably from about 5 to about 6, as measured in 30 ml of distilled water at 22° C.
- the resulting formulation comprises less than about 500 parts per million of residual alkalizing agent relative to the total weight of the composition.
- the composition comprises less than about 1000 parts per million of residual organic solvent and more preferably less than about 500 ppm.
- the resultant formulation maintains the stability of the benzimidazole derivative during storage and at the same time protects the product during passage through the acidic environment of the stomach.
- the problem of interaction between the enteric coat and the alkaline core is thus completely eliminated as the enteric coat at this stage does not release the free protons that are responsible for its acidic properties.
- the formulation has low levels of residual alkalinizing agent and residual organic solvent in the final product.
- the formulation of the present invention includes a substrate which features the benzimidazole derivative.
- a coating suspension which has a pH value of at least 6.5 and more preferably of from about 7 to about 10, is prepared with the enteric coating material.
- a pH value in the desired range is obtained by adding an alkalinizing agent to an enteric coating material
- the alkalinizing agent is selected from the group consisting of basic sodium, potassium, methanolamine or ammonium hydroxide, amino alcohols and alkylene diamines, arginine, and lysine.
- This enteric coating solution is then layered directly over the substrate to form the composition of the present invention.
- substrate refers to substantially any structure which features the benzimidazole derivative, such as Omeprazole.
- this structure could be an active core containing the benzimidazole derivative.
- the active core may comprise, for example, a pellet, a bead, or a tablet.
- This active core could be prepared in a number of different ways which are known in the art.
- the active core could be formed by compressing the benzimidazole derivative with an alkaline substance.
- the active core could be prepared by mixing the benzimidazole derivative with an alkaline substance, spheronizing the mixture and then forming cores through pelletisation.
- the active core is optionally and preferably prepared by embedding the active ingredient in a poloxamer and compressing the embedded material into tablets.
- the active core is also optionally formed by granulating the active ingredient with an alkaline substance and compressing the granulation into tablets.
- the structure could include a neutral core, such as a sugar bead which does not contain the benzimidazole derivative, over which the benzimidazole derivative is coated.
- the coating includes Omeprazole or other benzimidazole derivative with a suitable adhesive polymer.
- the pellet may optionally be prepared by spheronization and pelletization of the benzimidazole derivative and a suitable binding agent.
- the benzimidazole derivative of the present invention may comprise, for example, Omeprazole, Pantoprazole, Lansoprazole, Leminoprazole, Perprazole, or Rabeprazole, or pharmaceutically acceptable salts thereof.
- the benzimidazole derivative is omeprazole.
- the substrate may further comprise a filler.
- suitable fillers include microcrystalline cellulose, sodium carboxymethycellulose, ethylcellulose, cellulose acetate, starch, lactose, glucose, fructose, sucrose, dicalcium phosphate, sorbitol, manitol, mantitol, lactitol, xylitol, isomalt, erythritol, and hydrogenated starch hydrolysates, or a mixture thereof.
- the substrate may comprise a disintegrant, such as, for example, low-substituted carboxymethyl cellulose sodium, cross-linked polyvinyl pyrrolidone, sodium starch glycolate, cross-linked sodium carboxymethyl cellulose, pregelatinized starch, microcrystalline starch, water insoluble starch, calcium carboxymethyl cellulose, and low substituted hydroxypropyl cellulose magnesium aluminum silicate, or a mixture thereof.
- a disintegrant such as, for example, low-substituted carboxymethyl cellulose sodium, cross-linked polyvinyl pyrrolidone, sodium starch glycolate, cross-linked sodium carboxymethyl cellulose, pregelatinized starch, microcrystalline starch, water insoluble starch, calcium carboxymethyl cellulose, and low substituted hydroxypropyl cellulose magnesium aluminum silicate, or a mixture thereof.
- the substrate may further comprise a lubricant, such as, for example, sodium stearyl fumarate, polyethylene glycol, silica colloidal anhydrous and magnesium stearate, or a mixture thereof.
- a lubricant such as, for example, sodium stearyl fumarate, polyethylene glycol, silica colloidal anhydrous and magnesium stearate, or a mixture thereof.
- the substrate may optionally further comprises an alkalinizing agent, such as, for example, sodium stearate, meglumine, disodium phosphate, magnesium carbonate, and ammonia, or a mixture thereof.
- an alkalinizing agent such as, for example, sodium stearate, meglumine, disodium phosphate, magnesium carbonate, and ammonia, or a mixture thereof.
- Substantially any type of neutralized suitable enteric coating material could be used in order to coat the benzimidazole substrate, including but not limited to, cellulose acetate phthalate (CAP); hydroxypropyl methylcellulose phthalate (HPMCP); polyvinyl acetate phthalate; cellulose acetate trimellitate; poly((methacrylic acid, methyl methacrylate)1:1) (Eudragit L100TM), poly((methacrylic acid, ethyl acrylate)1:1) (Eudragit L30D-55) or Eudragit L100-55TM, (poly(methacrylic acid, methyl methacrylate)1:2) EudragitTM, hypromellose acetate succinate (HPMCAS), sodium alginate, and alginic acid or mixtures thereof.
- CAP cellulose acetate phthalate
- HPMCP hydroxypropyl methylcellulose phthalate
- HPP hydroxypropyl methylcellulose phthalate
- neutralized enteric coating material refers to enteric coating material which has been at least partially neutralized by reaction with an alkalizing agent.
- alkalizing agents for neutralizing the enteric polymer include, but are not limited, to amino alcohols such as methanolamine, monoethanol amine, propanolamine and alkylene diamines such as methylene diamine, ethylene diamine, propylene diamine, and ammonia solution such as ammonium hydroxide, basic ammonium salts, arginine, lysine and any other pharmaceutically acceptable amino compound bases, or a combination thereof.
- the enteric coating material is at least about 60% neutralized, more preferably the enteric coating material is at least about 80% neutralized, and most preferably the enteric coating material is at least about 95% neutralized.
- the enteric coating is optionally prepared in an organic solvent, such as, for example, acetone, ethanol or isopropanol, or a combination thereof; such as a mixture of ethanol and water (30/70 or 40/60); or a mixture of isopropyl alcohol and ethanol.
- organic solvent such as, for example, acetone, ethanol or isopropanol, or a combination thereof; such as a mixture of ethanol and water (30/70 or 40/60); or a mixture of isopropyl alcohol and ethanol.
- the enteric coating optionally contains at least one of a plasticizer (such, as for example, a citric acid ester or a phthalic acid ester), a surfactant (such as, for example, polysorbate 80 or sodium lauryl sulfate), a glidant (such as, for example, talc or titanium dioxide), a coloring agent and a polishing agent.
- a plasticizer such as for example, a citric acid ester or a phthalic acid ester
- a surfactant such as, for example, polysorbate 80 or sodium lauryl sulfate
- a glidant such as, for example, talc or titanium dioxide
- a coloring agent such as, for example, talc or titanium dioxide
- the method for applying the enteric coating material to the substrate can vary.
- any coating method can be used, such as pan coating or fluidized bed coating, with the solution of the enteric coat chosen.
- Example 1 A preferred embodiment of the formulation of the present invention is presented in Example 1 below. Residual akalinizing agent in the coating was analyzed as described in Examples 2 and 3, respectively.
- Omeprazole was thoroughly mixed with lactose, sodium starch glycolate, sodium stearate and sodium stearyl fumarate. The mixture was then compressed into tablets weighing 250 mg each. The tablets were then transferred into a conventional coating pan and coated with the enteric coating, prepared as described below.
- the samples were analyzed according to Standard Methods for Examination of Water and Waste Water, Ed. 19, 1995, Method 4500-NH 3 F (phenate method).
- the samples were prepared in triplicate by adding 30 ml HPLC grade water to one tablet, shaking overnight on an inverting shaker, followed by centrifugation at 4000 rpm for 15 minutes. This solution was filtered through 2 layers of glass fiber cartridge (GFC) filters and analyzed according to the above mentioned method. Quantitation was performed using a calibration curve prepared from solutions of NH 4 Cl in water in the concentration range of 0.05 ⁇ g/mL to 1.0 ⁇ g/mL NH 3 . The uncoated tablets served as a control sample for the analysis of the coated tablets.
- Equipment Test tubes PP 50 ml Laboratory glassware Class A GFC filter paper 12.5 cm Whatman 1822-125 Shaker Heidolf Centrifuge capable of maintaining 4000 rpm
- Hydrochloric acid 4 N was prepared by mixing 83.3 mL of concentrated hydrochloric acid (specific gravity 1.19, 37%) with 200 mL water in a 250 mL volumetric flask. The volume was made up with water.
- Dilute hydrochloric acid was prepared by adding 1.2 mL hydrochloric acid (specific gravity 1.19, 37%) to a 1 L volumetric flask containing about 500 mL water, diluting to volume with water and mixing well.
- Mobile phase was prepared by mixing 600 mL of water with 400 mL acetonitrile, mixing well and sonicating to degas.
- dansyl chloride 0.2% dansyl chloride was prepared by weighing accurately about 100 mg dansyl chloride in a 50 mL volumetric flask and diluting with acetone.
- 0.1 M sodium hydrogen carbonate was prepared by weighing about 840 mg of sodium hydrogen carbonate into a 100 mL volumetric flask, diluting with water to give a pH of 9.0.
- Monoethenolamine standard stock solution (1000 ⁇ g/mL) was prepared in duplicate by weighing accurately about 100 mg of monoethanolamine into a 100 ml volumetric flask, dissolving and diluting with water.
- Monoethanolamine intermediate standard stock solution (100 ⁇ g/mL) was prepared by adding 5.0 mL standard stock solution to a 50 mL volumetric flask with dilute hydrochloric acid.
- Monoethanolamine working standard solution (10 ⁇ g/mL) was prepared from intermediate standard stock solution by adding 5.0 mL to a 50 mL volumetric flask with dilute hydrochloric acid.
- Test tubes were prepared in duplicate. One tablet was placed per 50 mL conical test tube and 50 mL of water added. Test tubes were placed on an inverting shaker at speed 6 for 2-3 hours, until disintegration of the tablets, then acidified by adding 200 ⁇ L of 4 N HCl. Test tubes were centrifuged for 15 minutes at 4000 rpm and filtered through Whatman GFC.
- the precision of the method was evaluated by replicate injections of a standard containing a nominal 10 ⁇ g/mL monoethanolamine derivatized according to the test method (system precision) and by preparing a sample of omeprazole tablets in 6 independent replicates according to the test method (method precision).
- mg ⁇ / ⁇ tablet area ⁇ ⁇ smp ⁇ Cst ⁇ 50 area ⁇ ⁇ st ⁇ 1000
- FIG. 5 A representative chromatogram is presented in FIG. 5 .
- Omeprazole tablets containing monoethanolamine were spiked at the 0.1% w/w level in triplicate.
- Omeprazole control tablets (no MEA) were spiked at three levels with 0.15, 0.3 and 0.9 mg/tablet, corresponding to 0.05, 0.1 and 0.3% w/w.
- the test was performed by transferring the tablets to 50 mL test tubes, adding suitable volumes of a solution of 1000 ⁇ g/mL MEA, followed by 50 ml of water and preparation according to the method described above.
- % ⁇ ⁇ recovery mg ⁇ / ⁇ tablet ⁇ ⁇ found ⁇ 100 average ⁇ ⁇ mg ⁇ / ⁇ tablet ⁇ ⁇ ( unspiked ) + mg ⁇ / ⁇ tablet ⁇ ⁇ added
- FIG. 6 A representative chromatogram of omeprazole tablets (analyst sample 3789 Batch BO415) spiked with MEA is presented in FIG. 6 .
- Enteric coated omeprazole tablets were prepared according to the composition of Example 1 (Batch #B0425).
- the enteric coating was prepared in aqueous dispersion, and the pH value of the coating dispersion was adjusted to the range from about 7 to about pH 9 by a combination of monoethanolamine and concentrated ammonia solution. The ammonia solution evaporated during the coating process.
- the coating films were fully disintegrated and fully dissolved (except for talc and the coloring powder of Sepisperse).
- the pH value of the medium was found to be 5.3. Hence, it is shown that the polymer retains its acidic properties and thus provides an acidic reaction.
- HPMCAS hydroxypropyl methylcellulose acetate succinate
- the native pH value of pure HPMCAS aqueous dispersion is about 4.5
- the pH value of about 5.3 found using the composition of the present invention may be due to the presence of residual monoethanolamine, which is used a second alkalizing agent for neutralization of HPMCAS.
- the present study shows that when the entering coating polymer is placed in purified water as test medium, a partial dissolution of the polymer first takes place, which continues for as long as the pH of the medium remains basic. Once the pH of the medium reaches an acidic value of about 5.4, dissolution of the polymer stops and the polymer disintegrates. In diluted neutral buffer solution-1% simulated intestinal fluid, on the other hand, an acidic pH was achieved only after full polymer dissolution.
- the temporarily neutralized HPMCAS coating prepared using a high concentration of ammonia during the coating process provides an enteric film coat surrounding the omeprazole-containing cores which can withstand pH values of up to about 5. This can provide the active material with an appropriate protection while passing through the stomach even if the pH values of gastric fluid are elevated.
Abstract
A benzimidazole formulation which lacks an intermediate layer and yet which is stable both during storage and during the passage through the stomach, and which has low levels of residual volatile excipients, including but not limited to residual alkalinizing agents and/or residual solvents.
Description
- The present invention relates to a novel stable formulation for an acid labile benzimidazole, and methods of preparation and administration thereof, and in particular, for a stable formulation of a benzimidazole which is suitable for oral administration, and has low levels of residual volatile excipients such as solvents.
- Omeprazole, Pantoprazole, Lansoprazole and other derivatives of benzimidazole, which are active proton pump inhibitors and used conventionally for decreasing gastric secretion are known to be susceptible to degradation and transformation in acid media. Omeprazole, 5-methoxy-2(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole, is disclosed and described in European Patent No. 5129 and European Patent No. 124495, as well as in numerous other patents and published patent applications.
- The susceptibility of these active proton pump inhibitor substances to degradation and transformation in acid media increases the difficulty of preparing a pharmaceutical form designed for oral administration. If the active substance comes into contact with the stomach content, which is a highly acidic medium, these chemical substances become degraded. Thus, these benzimidazole derivatives should be protected both during storage and during their passage through the acidic environment of the stomach.
- The stability of Omeprazole has been extensively studied (see for example A. Pilbrant and C. Cederberg, Scan. J. Gastroenterol., 20: 113-120, 1985). Omeprazole degrades with a half-life of less than 10 minutes in an environment with pH values below 4.0. At pH 6.5, the half life of Omeprazole is 18 hours and at pH 11 about 300 days. Therefore, the environment of Omeprazole should be kept at a sufficiently high pH value in order to maintain the stability of the compound, in a formulation which is suitable as a product for oral administration, for example by locating Omeprazole within a core which also contains alkaline constituents. This leads to an alkaline reaction aimed at improving stability of the active substance during manufacture thereof and during storage of the pharmaceutical formulation.
- In addition, such a formulation must protect Omeprazole from the acidic environment of the stomach, since if Omeprazole is given orally without any protective coating, it will degrade in the acid environment of the stomach. European Patent No. 237,200 discloses one solution, which is to directly coat the solid core containing Omeprazole, or another benzimidazole derivative, with an enteric coating layer.
- However, this apparent solution to the instability of Omeprazole caused further complications, in that the alkaline core containing Omeprazole was found to react with the enteric coating, thereby causing the enteric coating to degrade. A solution to these further complications is disclosed in United Kingdom Patent Application No. 2,189,698, in which Omeprazole is contained within a solid active core, which is coated first with a subcoating layer and then with an enteric coating layer. The enteric coating layer protects the Omeprazole during the passage through the stomach, while the subcoating layer protects the enteric coating layer from reacting negatively with the alkaline core containing Omeprazole.
- The background art describes other attempts to provide formulations which are suitable for oral administration of acid-labile substances. For example, PCT Application No. WO 97/12581 discloses a composition adapted for oral administration containing Omeprazole which specifically does not include alkaline-reacting compounds. Instead, the composition features a core composed of a nuclei and Omeprazole compressed together, an intermediate layer and an enteric layer.
- European Patent Application No. 519,144 discloses a formulation for Omeprazole, which features a neutral (sugar) core. Omeprazole is sprayed onto the sugar core, after which an intermediate coating layer and an enteric coating layer are sprayed onto the core.
- PCT Application No. WO 98/00114 discloses a modification to other background art formulations for Omeprazole, in which the intermediate subcoating layer is partially neutralized with an alkaline compound. However, this modified formulation still features the subcoating layer, which is a disadvantage in that it complicates the manufacturing process and increases the expense and difficulty of manufacture. Thus, the formulation disclosed in PCT Application No. WO 98/00114, like those disclosed in European Patent Application No. 519,144 and other background art references, has the disadvantage of requiring the intermediate layer.
- PCT Application No. WO 83/00435 discloses a solid dosage form, such as a capsule or tablet, containing a pharmacologically active agent coated with an anionic polymer, which is insoluble in gastric juice and in intestinal juice below pH 7. The preferred anionic polymer is a partly methyl esterified methacrylic acid polymer in which the ratio of free carboxylic groups to ester groups is about 1:2. In contrast to the present invention, Omeprazole is not disclosed as one of the active agents.
- French Application No. 2,692,146 discloses stable compositions of microgranules of gastro-protected Omeprazole. The composition features a center of Omeprazole diluted in mannitol. This center is coated with an intermediate layer featuring mannitol. An enteric coating is then added over this intermediate layer. PCT Application No. WO 97/12581 discloses a formulation in which an intermediate layer between the core and an enteric coating contains silicium dioxide.
- PCT Application No. WO 96/37195 discloses a formulation which lacks a subcoating layer, but which features a core containing titanium dioxide. Both the core containing Omeprazole and the enteric coating layer placed on top of the core include titanium dioxide as an ingredient. Unfortunately, titanium dioxide is only able to mask the discoloration caused by the reaction between Omeprazole and the enteric coating layer, but cannot prevent such an undesirable reaction. Thus, the disclosed formulation does not prevent the undesirable reaction between the benzimidazole derivative and the enteric coating, which is known in the art.
- German Patent Application No. 196 26 045 A1 discloses a method for stabilising Omeprazole by coating small tablets or pellets, containing large amounts of mannitol, with a subcoating of Eudragit L. The subcoating of Eudragit L is neutralized, after which a final enteric coat of non-neutralized Eudragit L is applied.
- A formulation of a benzimidazole derivative, such as Omeprazole, which lacks an intermediate coating layer and yet which is stable both during storage and during the passage through the stomach, is described in U.S. patent application Ser. No. 10/018,992. This formulation involves neutralization of the enteric coating with an alkaline compound, such as ammonium hydroxide. The formulation is simple to manufacture and exposes the sensitive benzimidazole derivative to fewer production steps, thereby decreasing degradation of the active compound during production.
- However, neutralization of enteric coatings with an alkalinizing agent usually results in a certain amount of the alkalinizing agent remaining in the final product. Furthermore, benzimidazole formulations are frequently prepared using volatile organic solvents, a residual amount of which is also found in the final product. Since there is no therapeutic benefit from residual alkalinizing agents and residual solvents, and these may, in fact, have a harmful effect, it is desirable to keep the levels of such residual solvents as low as possible for toxicity/safety reasons.
- The background art does not teach or suggest a benzimidazole formulation, particularly for Omeprazole, which lacks an intermediate layer and yet which is stable both during storage and during the passage through the stomach, and which has low levels of residual alkalinizing agents and residual solvents.
- The present invention overcomes these drawbacks of the background art by providing a benzimidazole formulation which lacks an intermediate layer and yet which is stable both during storage and during the passage through the stomach, and which has low levels of residual volatile excipients, including but not limited to residual alkalinizing agents and/or residual solvents.
- According to some embodiments of the present invention, there is provided a stable composition for a benzimidazole derivative, the composition comprising a substrate, comprising the benzimidazole derivative; and a single coating layer consisting essentially of at least one neutralized enteric polymer, the enteric polymer having been neutralized by an alkalizing agent. The alkalizing agent is selected from the group consisting of amino alcohols, alkylene diamines, ammonia solution, arginine and lysine. Optionally and preferably there is a single coating layer layered directly over the substrate, without an intermediate layer between the substrate and the enteric coating. The composition comprises less than about 500 parts per million of residual alkalizing agent relative to the total weight of the composition.
- According to some embodiments of the present invention, there is provided a stable composition for a benzimidazole derivative, the composition comprising a substrate comprising the benzimidazole derivative and a single coating layer consisting of one or more enteric polymers treated by at least one volatile alkalizing agent prior to applying over the substrate. The composition comprises less than 500 parts per million of residual volatile alkalizing agents relative to the composition weight, and a pH of the coating layer is in the range of from about 4.5 to about 6.5 as measured in 30 ml of distilled water at 20-25° C.
- Optionally and preferably, the pH is in the range of from about 5 to about 6; more preferably the pH is about 5.
- Optionally and preferably, the alkalizing agent comprises at least one of basic sodium, potassium, methanolamine, ammonium solution (such as ammonium hydroxide), amino alcohols (such as methanolamine, monoethanol amine, or propanolamine, or combinations thereof), arginine, lysine, and alkylene diamines (such as methylene diamine, ethylene diamine, or propylene diamine, or combinations thereof).
- Optionally and preferably, the enteric polymer is dissolved in an organic solvent prior to application. Optionally and preferably, such a composition comprises less than about 1000 parts per million of residual organic solvent.
- Non-limiting examples of organic solvents include acetone, ethanol, isopropanol or a mixture thereof.
- Non-limiting examples of enteric polymers include cellulose acetate phthalate (CAP); hydroxypropyl methylcellulose phthalate (HPMCP); polyvinyl acetate phthalate; cellulose acetate trimellitate; poly((methacrylic acid, methyl methacrylate)1:1) (Eudragit L100™), poly((methacrylic acid, ethyl acrylate)1:1) (Eudragit L30D-55) or Eudragit L100-55™, (poly(methacrylic acid, methyl methacrylate)1:2) Eudragit™ S hydroxypropyl methylcellulose acetate succinate (HPMCAS), sodium alginate, and alginic acid or mixtures thereof.
- Optionally and preferably, the substrate is an active core for containing the benzimidazole derivative, such as, for example, a pellet, a bead or a tablet.
- Optionally and preferably, the active core is a tablet formed by compression.
- According to some embodiments of the present invention, the substrate features a neutral core; and an active coating containing the benzimidazole derivative, wherein the active coating is layered over the neutral core; such that the composition is in a form of a pellet.
- Optionally and preferably, the substrate features a core containing the benzimidazole derivative with a suitable binding agent, the core being prepared by spheronisation and pelletization; such that the composition is in a form of a pellet.
- The benzimidazole is optionally one or more of Omeprazole, Pantoprazole, Lansoprazole, Leminoprazole, Perprazole, Rabeprazole, or pharmaceutically acceptable salts thereof, or combinations thereof.
- Optionally, the substrate further comprises a filler, such as, for example, one or more of microcrystalline cellulose, sodium carboxymethycellulose, ethylcellulose, cellulose acetate, starch, lactose, glucose, fructose, sucrose, dicalcium phosphate, sorbitol, mannitol, mantitol, lactitol, xylitol, isomalt, erythritol, and hydrogenated starch hydrolysates, or a mixture thereof.
- Optionally, the substrate further comprises a disintegrant, such as, for example, one or more of low-substituted carboxymethyl cellulose sodium, cross-linked polyvinyl pyrrolidone, sodium starch glycolate, cross-linked sodium carboxymethyl cellulose, pregelatinized starch, microcrystalline starch, water insoluble starch, calcium carboxymethyl cellulose, and low substituted hydroxypropyl cellulose magnesium aluminum silicate, or a mixture thereof.
- Optionally, the substrate further comprises a lubricant, such as, for example, one or more of sodium stearyl fumarate, polyethylene glycol, silica colloidal anhydrous and magnesium stearate, or a mixture thereof.
- Optionally, the substrate further comprises an alkalinizing agent, such as, for example, one or more of sodium stearate, meglumine, disodium phosphate, and ammonia, or a mixture thereof.
- Optionally, the coating layer further comprises a plasticizer, such as, for example, one or more of a citric acid ester and a phthalic acid ester.
- Optionally, the coating layer further comprises a surfactant, such as, for example, one or more of polysorbate 80 and sodium lauryl sulfate.
- Optionally, the coating layer further comprises a glidant, such as, for example one or more of talc and titanium dioxide.
- Optionally, the coating layer further comprises at least one of a coloring agent and a polishing agent.
- According to some embodiments there is provided a method for preparing a stable composition for a benzimidazole derivative, the method comprising neutralizing one or more enteric polymers with at least one volatile alkalizing agent; and layering the enteric polymer(s) over a substrate comprising the benzimidazole derivative to form a coating layer, the composition comprising the substrate and the coating layer, such that the composition comprises less than 1000 parts per million of residual volatile alkalizing agents relative to composition weight.
- Optionally, the alkalizing agent comprises one or more of amino alcohols, alkylene diamines, arginine, lysine, and ammonia solution.
- According to some embodiments, there is provide a method for preparing a stable composition for a benzimidazole derivative, the method comprising dissolving one or more enteric polymers in an organic solvent; neutralizing the enteric polymer(s) with at least one volatile alkalizing agent; and layering the enteric polymer(s) over a substrate comprising the benzimidazole derivative to form a coating layer, the composition comprising the substrate and the coating layer, such that the composition comprises less than 1000 parts per million of residual solvent relative to composition weight.
- The invention is herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of the preferred embodiments of the present invention only, and are presented in the cause of providing what is believed to be the most useful and readily understood description of the principles and conceptual aspects of the invention. In this regard, no attempt is made to show structural details of the invention in more detail than is necessary for a fundamental understanding of the invention, the description taken with the drawings making apparent to those skilled in the art how the several forms of the invention may be embodied in practice.
- In the drawings:
-
FIGS. 1-6 relate to the suitability of test method for determination of residual monoethanolamine. - The formulation of the present invention contains a benzimidazole derivative, such as Omeprazole, and is able to maintain the stability of this active ingredient without a separating layer between the active compound and an enteric coating layer. Instead, the enteric coating layer is prepared as an aqueous dispersion or in organic solvent and neutralized with an alkalinizing agent, before being applied as a solution directly to the benzimidazole derivative substrate.
- Preferably, the aqueous dispersion has a pH in the range of at least 6.5, and more preferably in the range of from about 7 to about 10.
- After being applied to the substrate, the aqueous dispersion dries to form a coating layer, preferably having a pH in the range of from about 4.5 to about 6.5, and more preferably from about 5 to about 6, as measured in 30 ml of distilled water at 22° C.
- The resulting formulation comprises less than about 500 parts per million of residual alkalizing agent relative to the total weight of the composition.
- Preferably, the composition comprises less than about 1000 parts per million of residual organic solvent and more preferably less than about 500 ppm.
- The resultant formulation maintains the stability of the benzimidazole derivative during storage and at the same time protects the product during passage through the acidic environment of the stomach. The problem of interaction between the enteric coat and the alkaline core is thus completely eliminated as the enteric coat at this stage does not release the free protons that are responsible for its acidic properties. At the same time, the formulation has low levels of residual alkalinizing agent and residual organic solvent in the final product.
- The preparation of the benzimidazole-containing compositions of the present invention is described first with reference to the following general description and then with reference to the following non-limiting examples of the preparation and application of the compositions of the present invention.
- The formulation of the present invention includes a substrate which features the benzimidazole derivative. A coating suspension, which has a pH value of at least 6.5 and more preferably of from about 7 to about 10, is prepared with the enteric coating material. Preferably, a pH value in the desired range is obtained by adding an alkalinizing agent to an enteric coating material
- More preferably, the alkalinizing agent is selected from the group consisting of basic sodium, potassium, methanolamine or ammonium hydroxide, amino alcohols and alkylene diamines, arginine, and lysine. This enteric coating solution is then layered directly over the substrate to form the composition of the present invention.
- The term “substrate” refers to substantially any structure which features the benzimidazole derivative, such as Omeprazole. For example, this structure could be an active core containing the benzimidazole derivative. The active core may comprise, for example, a pellet, a bead, or a tablet. This active core could be prepared in a number of different ways which are known in the art. For example, the active core could be formed by compressing the benzimidazole derivative with an alkaline substance. As another example, the active core could be prepared by mixing the benzimidazole derivative with an alkaline substance, spheronizing the mixture and then forming cores through pelletisation. As yet another example, the active core is optionally and preferably prepared by embedding the active ingredient in a poloxamer and compressing the embedded material into tablets. The active core is also optionally formed by granulating the active ingredient with an alkaline substance and compressing the granulation into tablets.
- Alternatively and optionally, the structure could include a neutral core, such as a sugar bead which does not contain the benzimidazole derivative, over which the benzimidazole derivative is coated. The coating includes Omeprazole or other benzimidazole derivative with a suitable adhesive polymer. The pellet may optionally be prepared by spheronization and pelletization of the benzimidazole derivative and a suitable binding agent.
- The benzimidazole derivative of the present invention may comprise, for example, Omeprazole, Pantoprazole, Lansoprazole, Leminoprazole, Perprazole, or Rabeprazole, or pharmaceutically acceptable salts thereof. Preferably, the benzimidazole derivative is omeprazole.
- Optionally, the substrate may further comprise a filler. Examples of suitable fillers include microcrystalline cellulose, sodium carboxymethycellulose, ethylcellulose, cellulose acetate, starch, lactose, glucose, fructose, sucrose, dicalcium phosphate, sorbitol, manitol, mantitol, lactitol, xylitol, isomalt, erythritol, and hydrogenated starch hydrolysates, or a mixture thereof.
- Further optionally, the substrate may comprise a disintegrant, such as, for example, low-substituted carboxymethyl cellulose sodium, cross-linked polyvinyl pyrrolidone, sodium starch glycolate, cross-linked sodium carboxymethyl cellulose, pregelatinized starch, microcrystalline starch, water insoluble starch, calcium carboxymethyl cellulose, and low substituted hydroxypropyl cellulose magnesium aluminum silicate, or a mixture thereof.
- Also optionally, the substrate may further comprise a lubricant, such as, for example, sodium stearyl fumarate, polyethylene glycol, silica colloidal anhydrous and magnesium stearate, or a mixture thereof.
- The substrate may optionally further comprises an alkalinizing agent, such as, for example, sodium stearate, meglumine, disodium phosphate, magnesium carbonate, and ammonia, or a mixture thereof.
- Substantially any type of neutralized suitable enteric coating material could be used in order to coat the benzimidazole substrate, including but not limited to, cellulose acetate phthalate (CAP); hydroxypropyl methylcellulose phthalate (HPMCP); polyvinyl acetate phthalate; cellulose acetate trimellitate; poly((methacrylic acid, methyl methacrylate)1:1) (Eudragit L100™), poly((methacrylic acid, ethyl acrylate)1:1) (Eudragit L30D-55) or Eudragit L100-55™, (poly(methacrylic acid, methyl methacrylate)1:2) Eudragit™, hypromellose acetate succinate (HPMCAS), sodium alginate, and alginic acid or mixtures thereof.
- As used herein, the term “neutralized enteric coating material” refers to enteric coating material which has been at least partially neutralized by reaction with an alkalizing agent. Suitable alkalizing agents for neutralizing the enteric polymer include, but are not limited, to amino alcohols such as methanolamine, monoethanol amine, propanolamine and alkylene diamines such as methylene diamine, ethylene diamine, propylene diamine, and ammonia solution such as ammonium hydroxide, basic ammonium salts, arginine, lysine and any other pharmaceutically acceptable amino compound bases, or a combination thereof.
- Preferably, the enteric coating material is at least about 60% neutralized, more preferably the enteric coating material is at least about 80% neutralized, and most preferably the enteric coating material is at least about 95% neutralized.
- The enteric coating is optionally prepared in an organic solvent, such as, for example, acetone, ethanol or isopropanol, or a combination thereof; such as a mixture of ethanol and water (30/70 or 40/60); or a mixture of isopropyl alcohol and ethanol.
- The enteric coating optionally contains at least one of a plasticizer (such, as for example, a citric acid ester or a phthalic acid ester), a surfactant (such as, for example, polysorbate 80 or sodium lauryl sulfate), a glidant (such as, for example, talc or titanium dioxide), a coloring agent and a polishing agent.
- The method for applying the enteric coating material to the substrate can vary. Substantially any coating method can be used, such as pan coating or fluidized bed coating, with the solution of the enteric coat chosen.
- A preferred embodiment of the formulation of the present invention is presented in Example 1 below. Residual akalinizing agent in the coating was analyzed as described in Examples 2 and 3, respectively.
- The following specific examples illustrate various aspects of the compositions of the present invention, and are not intended to be limiting in any way. Specific reference is made to Omeprazole for the purposes of description only and without intending to be limiting.
-
-
Pharmaceutical Amount Percent/ Ingredients function mg/tablet tablet Active constituent Omeprazole USP Active 20.00 6.51 Core Lactose monohydrate NF Filler 203.00 66.12 Sodium starch disintegrant 10.00 3.25 glycolate NF Sodium stearate NF alkalinizing agent 10.00 3.25 Sodium stearyl lubricant 7.00 2.28 fumarate NF Coating Hypromellose acetate enteric coating polymer 32.00 10.42 succinate NF Triethyl citrate NF plasticizer 4.50 1.47 Sodium lauryl sulfate wetting agent 0.50 0.16 NF Talc USP Glidant 8.14 2.65 Strong ammonium alkalinizing agent NA* — solution NF Monoethanolamine NF alkalinizing agent 1.00 0.33 Sepisperse AP 3527 coloring agent 10.80 3.52 Carnauba wax NF polishing agent 0.06 0.02 Purified water Solvent NA* — Total weight 307.00 Ca 100 *strong ammonium solution is used as a volatile alkalizing agent which is evaporated during the coating process. - Preparation of the substrate: Omeprazole was thoroughly mixed with lactose, sodium starch glycolate, sodium stearate and sodium stearyl fumarate. The mixture was then compressed into tablets weighing 250 mg each. The tablets were then transferred into a conventional coating pan and coated with the enteric coating, prepared as described below.
-
- Coating A: triethyl citrate was dissolved in water, sodium lauryl sulfate was then added to this solution, HPMCAS and talc were dispersed in this solution, such that the concentration of HPMCAS was about 7% weight per volume. Monoethanolamine was added to this dispersion. Ammonia in a 25% solution was added to adjust the pH value in a range of from about 7 to about pH 9. The pigment was then added to the enteric coating dispersion.
- Coating B: Triethyl citrate was dissolved in a mixture of isopropyl alcohol and alcohol, sodium lauryl sulfate was then added to this solution, HPMCAS and talc were dispersed in this solution, such that the concentration of HPMCAS was about 6% weight per volume. Ammonia in a 25% solution was added to adjust the pH value in a range of from about 7 to about pH 9. The pigment was then added to the enteric coating dispersion. The tablet cores were then transferred into a conventional coating pan and coated with the enteric coating layer.
- Coating C: Triethyl citrate was dissolved in water to form an aqueous solution; sodium lauryl sulfate was then added to this aqueous solution. HPMCAS, colloidal silicon dioxide and talc were dispersed in this solution, such that the concentration of HPMCAS was about 7% weight per volume. Ammonia in a 25% solution was added to adjust the pH value of the coating dispersion in a range of from about 7 to about pH 9.
- Coating D: Triethyl citrate was dissolved in water to form an aqueous solution; sodium lauryl sulfate was then added to this aqueous solution. HPMCAS, talc, and monoethanolamine were dispersed in this solution. Ammonia in a 25% solution was added to adjust the pH value of the coating dispersion in a range of from about 7 to about pH 9.
- Samples were stored at room temperature prior to analysis.
- The samples were analyzed according to Standard Methods for Examination of Water and Waste Water, Ed. 19, 1995, Method 4500-NH3 F (phenate method). The samples were prepared in triplicate by adding 30 ml HPLC grade water to one tablet, shaking overnight on an inverting shaker, followed by centrifugation at 4000 rpm for 15 minutes. This solution was filtered through 2 layers of glass fiber cartridge (GFC) filters and analyzed according to the above mentioned method. Quantitation was performed using a calibration curve prepared from solutions of NH4Cl in water in the concentration range of 0.05 μg/mL to 1.0 μg/mL NH3. The uncoated tablets served as a control sample for the analysis of the coated tablets.
- Results are presented in Table 1.
-
TABLE 1 Batch No. (based on Lab no. Example 1) NH3 mg/tablet 3789 BO415 (coated) 0.011; 0.07; 0.011 Mean 0.010 3980 BO425 (coated) 0.09; 0.010; 0.010 Mean 0.010 3981 BO515 (coated) 0.010; 0.012; 0.011 Mean 0.011 - Samples were stored at room temperature prior to analysis.
-
Materials Dansyl chloride Across 1158500 Sodium hydrogen carbonate Merck 106329 Acetone J. T. Baker 9002 Acetonitrile J. T. Baker 9017 Sodium hydroxide J. T. Baker 3722 Water HPLC grade Milli-Q in-house Monoethanolamine Analyst sample 5015 Hydrochloric acid Riedel de Haen 30721 -
Equipment Test tubes PP 50 ml Laboratory glassware Class A GFC filter paper 12.5 cm Whatman 1822-125 Shaker Heidolf Centrifuge capable of maintaining 4000 rpm -
HPLC instrument and conditions Apparatus: Agilent 1100 with variable wavelength detector and autosampler and Chemstation Rev A 10.01 software Column: Symmetry C 18 4.6 × 150 mm, 3.5 μ Injection volume: 10 μL Flow rate: 1.0 mL/min Detection: 254 nm Column temperature: ambient Run time: 10 minutes Retention time of −5.3 minutes MEA derivative: - Hydrochloric acid 4 N was prepared by mixing 83.3 mL of concentrated hydrochloric acid (specific gravity 1.19, 37%) with 200 mL water in a 250 mL volumetric flask. The volume was made up with water.
- Dilute hydrochloric acid was prepared by adding 1.2 mL hydrochloric acid (specific gravity 1.19, 37%) to a 1 L volumetric flask containing about 500 mL water, diluting to volume with water and mixing well.
- Mobile phase was prepared by mixing 600 mL of water with 400 mL acetonitrile, mixing well and sonicating to degas.
- 0.2% dansyl chloride was prepared by weighing accurately about 100 mg dansyl chloride in a 50 mL volumetric flask and diluting with acetone.
- 0.1 M sodium hydrogen carbonate was prepared by weighing about 840 mg of sodium hydrogen carbonate into a 100 mL volumetric flask, diluting with water to give a pH of 9.0.
- Monoethenolamine standard stock solution (1000 μg/mL) was prepared in duplicate by weighing accurately about 100 mg of monoethanolamine into a 100 ml volumetric flask, dissolving and diluting with water.
- Monoethanolamine intermediate standard stock solution (100 μg/mL) was prepared by adding 5.0 mL standard stock solution to a 50 mL volumetric flask with dilute hydrochloric acid.
- Monoethanolamine working standard solution (10 μg/mL) was prepared from intermediate standard stock solution by adding 5.0 mL to a 50 mL volumetric flask with dilute hydrochloric acid.
- Samples were prepared in duplicate. One tablet was placed per 50 mL conical test tube and 50 mL of water added. Test tubes were placed on an inverting shaker at speed 6 for 2-3 hours, until disintegration of the tablets, then acidified by adding 200 μL of 4 N HCl. Test tubes were centrifuged for 15 minutes at 4000 rpm and filtered through Whatman GFC.
- The procedure was performed on water as control and on all standards and samples, directly in autosampler vials.
- 100 μL of water, standard or sample solution was mixed with 200 μL 0.2% dansyl chloride solution. 400 μL 0.1 M sodium hydrogen carbonate and 400 μL acetone were added. The vials were closed, mixed and heated for 20 minutes in a water bath at 60° C. The contents of the vials were cooled to room temperature and injected into the HPLC system.
- Results are presented in Table 2.
-
TABLE 2 Lab no. Sample name Monoethanolamine mg/tablet 3789 BO415 0.77 (% RSD = 6.0) 3980 BO425 0.730; 0.681 Mean 0.71 3981 BO515 0.822; 0.755 Mean 0.79 5273 BO615 0.908; 0.780 Mean 0.84 - In order to evaluate the suitability of the method as described above, the method was evaluated for specificity, linearity, precision (system and method) and recovery.
- In order to demonstrate the specificity, the following samples and solutions were analyzed: a sample blank (water); a standard containing 10 μg/mL monoethanolamine that had undergone the derivatization procedure; omeprazole tablets, prepared without the use of monoethanolamine, prepared according to the test method; and water.
- As shown in
FIGS. 1 to 6 , no interfering peaks at the retention time of monoethanolamine were recorded in the chromatograms of the blank sample, water, or the tablet without monoethanolamine. - The linearity of the method was demonstrated in the range of from 1 to 50 μg/mL monoethanolamine, corresponding to 0.05 to 2.5 mg/tablet. Results are presented in Table 3.
-
TABLE 3 Concentration (μg/mL) Peak area mAU*s % difference 0/96 7.4978E±00 43.7 1.92 1.5817E±01 10.9 4.81 4.4112E±01 −2.5 9.62 9.2365E±01 −6.0 19.24 2.0443 ± 02 −0.4 48.10 5.2640 ± 02 0.3 correlation 0.99982 square correlation 0.99963 slope 1.1074E+01 intercept −7.8104E+00 −7.6 - The precision of the method was evaluated by replicate injections of a standard containing a nominal 10 μg/mL monoethanolamine derivatized according to the test method (system precision) and by preparing a sample of omeprazole tablets in 6 independent replicates according to the test method (method precision).
- The system precision results as presented in Table 4 show that good precision was obtained for the peak areas as well as for the retention times.
-
TABLE 4 Replicate Retention time (min) Peak areas mAU*s 1 5.291 9.0628E+01 2 5.286 8.9055E+01 3 5.283 9.1252E+01 4 5.283 8.8879E+01 5 5.262 8.9296E+01 6 5.225 9.0930E+01 Mean 5.272 9.0007E+01 % RSD 0.5 1.2 - Method precision was performed using 6 preparations of omeprazole tablets (analyst sample 3789). Results were calculated against a standard containing 9.62 μg/mL monothenaolamine with an average peak area of 9.5519E+01 mAU*s, using the following formula:
-
- area smp=monoethanolamine peak area in sample chromatogram
- area st=average peak area of standard “10 μg/mL”
- cst=standard concentration in μg/mL
- 50=sample extraction volume (mL)
- 1000=conversion factor of μg to mg
- A representative chromatogram is presented in
FIG. 5 . - Method precision data and results are presented in Table 5.
-
TABLE 5 Analyst Concentration of MEA in no. and Sample MEA peak MEA in sample tablets replicate name area mAU*s solution (μg/mL) mg/tablet 3789-1 coated 1.4518E+0.2 14.6 0.731 3789-2 BO4 15 1.6711E+0.2 16.8 0.842 3789-3 1.4151E+0.2 14.3 0.713 3789-4 1.5385E+0.2 15.5 0.775 3789-5 1.5710E+0.2 15.8 0.791 3789-6 1.5804E+0.2 15.9 0.796 MEAN 0.774 % RSD 6.0 - The recovery of the method was demonstrated by spiking control (no monoethanolamine) and monoethanolamine-containing omeprazole tablets with three levels of monoethanolamine.
- Omeprazole tablets containing monoethanolamine (sample 3789, batch BO415) were spiked at the 0.1% w/w level in triplicate. Omeprazole control tablets (no MEA) were spiked at three levels with 0.15, 0.3 and 0.9 mg/tablet, corresponding to 0.05, 0.1 and 0.3% w/w. The test was performed by transferring the tablets to 50 mL test tubes, adding suitable volumes of a solution of 1000 μg/mL MEA, followed by 50 ml of water and preparation according to the method described above.
- Results as presented in Tables 6 and 7 show good recovery results, within generally accepted limits for residue analysis. Recovery results were calculated against a standard containing 9.62 μg/mL MEA with an average peak area of 9.5519E+01 mAU*s. The recovery results in the tablets containing MEA were calculated as follows:
-
- A representative chromatogram of omeprazole tablets (analyst sample 3789 Batch BO415) spiked with MEA is presented in
FIG. 6 . -
TABLE 6 Analyst Spiking Concentration of No. and Sample MEA peak level in MEA in sample MEA in % replicate name area (mAu*s) mg/tablet solution (μg/mL) tablets recovery 5274-1 omeprazole 0.0000E+00 0.0 0.000 5274-2 20 mg 0.0000E+00 0.0 0.000 5274-3 uncoated 0.0000E+00 0.0 0.000 100605 Mean 0.000 5274-1 omeprazole 2.4417E+0.1 0.144 2.46 0.123 85.5 5274-2 20 mg 2.4339E+01 2.45 0.123 85.2 5274-3 uncoated 2.4966E+01 2.51 0.126 87.4 100605 Mean 0.124 86.0 % RSD 1.4 1.4 5274-1+0.1% omeprazole 4.9693E+01 0.289 5.00 0.252 87.2 5274-2+0.1% 20 mg 5.1115E+01 5.15 0.259 89.7 5274-3+0.1% uncoated 5.1356E+01 5.17 0.260 90.1 100605 Mean 0.257 89.0 % RSD 1.8 1.8 5274-1+0.3% Omeprazole 1.845E+02 0.962 18.59 0.948 98.5 5274-2+0.3% 20 mg 1.8919E+02 19.05 0.972 101.0 5274-3+0.3% uncoated 1.8982E+02 19.12 0.975 101.4 100605 Mean 0.965 100.3 % RSD 1.5 1.5 -
TABLE 7 Analyst Spiking Concentration of MEA in No. and Sample MEA peak level MEA in sample tablet % replicate name area mAU*s mg/tablet solution μg/mL mg/tablet recovery 3789-1 coated 1.4518E+02 14.6 0.731 3789-2 BO415 1.6711E+02 16.8 0.842 3789-3 1.4151E+02 14.3 0.713 Mean 0.762 % RSD 9.2 3789-1+0.1% coated 2.1507E+0.2 0.289 21.7 1.083 107.6 3789-2+0.1% B0415 2.1576E+0.2 21.7 1.086 107.9 3789-3+0.1% 2.3641E+0.2 23.8 1.1190 118.2 Mean 1.120 111.2 % RSD 5.5 5.5 - During the method development, stock solution stability was demonstrated for 48 hours at room temperature. In addition, it was found that the MEA derivative is stable in autosampler vials at room temperature for at least 48 hours, because the response of the MEA derivative did not change upon reinjection.
- Enteric coated omeprazole tablets were prepared according to the composition of Example 1 (Batch #B0425). The enteric coating was prepared in aqueous dispersion, and the pH value of the coating dispersion was adjusted to the range from about 7 to about pH 9 by a combination of monoethanolamine and concentrated ammonia solution. The ammonia solution evaporated during the coating process.
-
- The pH of the coating layer following evaporation of the ammonia solution was measured in the following test solutions:
- 1. Purified water (pH 5.9 at 22° C.), obtained from MILI Q system; and
- 2. 1% buffer solution of Intestinal Fluid NF (pH 6.9 at 22° C.) using potassium dihydrogenphosphate (lot #B36148 purchased from Baker), and sodium hydroxide (lot #B452998549 from Merck), with no pancreatin added.
- For each test solution, three coated tablets were split and the core was removed by washing using purified water. The resulting film coats were then transferred into a vial containing 30 ml test solution, and stirred for 2 hours with a magnetic stirrer at 1000 rpm. The pH of the medium was determined.
- It was found that in purified water, the coating films partially disintegrated and partially dissolved. The pH value of the medium was found to be 5.4.
- In intestinal fluid, the coating films were fully disintegrated and fully dissolved (except for talc and the coloring powder of Sepisperse). The pH value of the medium was found to be 5.3. Hence, it is shown that the polymer retains its acidic properties and thus provides an acidic reaction.
- Since the pH of the coating solution was initially basic, it can be concluded that the change in pH occurs due to evaporation of ammonia solution, causing the polymer, hydroxypropyl methylcellulose acetate succinate (HPMCAS) to revert to its acid form, having enteric properties. The acidic form of HPMCAS can be soluble in water only through ionization of all free acidic groups in an aqueous medium with pH values above 5.5. This is in fact the reason that the polymer is characterized as an enteric polymer. While the native pH value of pure HPMCAS aqueous dispersion is about 4.5, the pH value of about 5.3 found using the composition of the present invention may be due to the presence of residual monoethanolamine, which is used a second alkalizing agent for neutralization of HPMCAS.
- The present study shows that when the entering coating polymer is placed in purified water as test medium, a partial dissolution of the polymer first takes place, which continues for as long as the pH of the medium remains basic. Once the pH of the medium reaches an acidic value of about 5.4, dissolution of the polymer stops and the polymer disintegrates. In diluted neutral buffer solution-1% simulated intestinal fluid, on the other hand, an acidic pH was achieved only after full polymer dissolution.
- The temporarily neutralized HPMCAS coating prepared using a high concentration of ammonia during the coating process provides an enteric film coat surrounding the omeprazole-containing cores which can withstand pH values of up to about 5. This can provide the active material with an appropriate protection while passing through the stomach even if the pH values of gastric fluid are elevated.
- It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination.
- Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims. All publications, patents and patent applications mentioned in this specification are herein incorporated in their entirety by reference into the specification, to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference. In addition, citation or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention.
Claims (42)
1. A stable composition for a benzimidazole derivative, the composition comprising:
a substrate, said substrate comprising the benzimidazole derivative; and
a single coating layer consisting essentially of at least one neutralized enteric polymer, wherein said enteric polymer is neutralized to a pH of at least 6.5 by at least two alkalizing agents prior to applying to said substrate, wherein said at least two alkalizing agents are is selected from the group consisting of amino alcohols, alkylene diamines, ammonia solution, arginine and lysine, said single coating layer layered directly over said substrate, without an intermediate layer between said substrate and said enteric coating,
wherein said composition comprises less than about 500 parts per million of residual alkalizing agent relative to the total weight of the composition.
2. A stable composition for a benzimidazole derivative, the composition comprising:
a substrate, said substrate comprising the benzimidazole derivative and
a single coating layer consisting of one or more enteric polymers treated by at least one volatile alkalizing agent prior to applying over the substrate to give a pH of at least 6.5;
wherein said composition comprises less than 500 parts per million of residual volatile alkalizing agents relative to composition weight,
and wherein a pH of said coating layer after being applied to said substrate is in the range of from about 4.5 to about 6.5 as measured in 30 ml of distilled water at 20-25° C.
3. The composition of claim 2 , wherein said pH of said coating layer after being applied to said substrate is in the range of from about 5 to about 6.
4. The composition of claim 3 , wherein said pH is about 5.
5. The composition of claim 1 , wherein said alkalizing agent is selected from the group consisting of basic sodium, potassium, methanolamine, ammonium solution, amino alcohols, arginine, lysine, and alkylene diamines.
6. The composition of claim 5 , wherein said amino alcohol is selected from the group consisting of methanolamine, monoethanol amine, and propanolamine.
7. The composition of claim 5 , wherein said alkylene diamine is selected from the group consisting of methylene diamine, ethylene diamine, and propylene diamine.
8. The composition of claim 5 , wherein said ammonium solution comprises ammonium hydroxide.
9. The composition of claim 1 , wherein said enteric polymer is dissolved in an organic solvent prior to application.
10. The composition of claim 9 , comprising less than about 1000 parts per million of residual organic solvent.
11. The composition of claim 9 , wherein said organic solvent is selected from the group consisting of acetone, ethanol, isopropanol and a mixture thereof.
12. The composition of claim 1 , wherein said enteric polymer is selected from the group consisting of cellulose acetate phthalate (CAP); hydroxypropyl methylcellulose phthalate (HPMCP); polyvinyl acetate phthalate; cellulose acetate trimellitate; poly((methacrylic acid, methyl methacrylate)1:1) (Eudragit L100™), poly((methacrylic acid, ethyl acrylate)1:1) (Eudragit L30D-55) or Eudragit L100-55™, (poly(methacrylic acid, methyl methacrylate)1:2) Eudragit™ S hydroxypropyl methylcellulose acetate succinate (HPMCAS), sodium alginate, and alginic acid or mixtures thereof.
13. The composition of claim 1 , wherein said substrate is an active core for containing the benzimidazole derivative.
14. The composition of claim 13 , wherein said active core is selected from the group consisting of a pellet, a bead and a tablet.
15. The composition of claim 14 , wherein said active core is a tablet formed by compression.
16. The composition of claim 1 , wherein said substrate features:
(i) a neutral core; and
(ii) an active coating containing the benzimidazole derivative, said active coating being layered over said neutral core;
such that the composition is in a form of a pellet
17. The composition of claim 1 , wherein said substrate features a core containing the benzimidazole derivative with a suitable binding agent, said core being prepared by spheronisation and pelletization; such that the composition is in a form of a pellet.
18. The composition of claim 1 , wherein the benzimidazole derivative is selected from the group consisting of Omeprazole, Pantoprazole, Lansoprazole, Leminoprazole, Perprazole, Rabeprazole, and pharmaceutically acceptable salts thereof.
19. The composition of claim 1 , wherein said substrate further comprises a filler.
20. The composition of claim 19 , wherein said filler is selected from the group consisting of microcrystalline cellulose, sodium carboxymethycellulose, ethylcellulose, cellulose acetate, starch, lactose, glucose, fructose, sucrose, dicalcium phosphate, sorbitol, manitol, mantitol, lactitol, xylitol, isomalt, erythritol, and hydrogenated starch hydrolysates, or a mixture thereof.
21. The composition of claim 1 , wherein said substrate further comprises a disintegrant.
22. The composition of claim 21 , wherein said disintegrant is selected from the group consisting of low-substituted carboxymethyl cellulose sodium, cross-linked polyvinyl pyrrolidone, sodium starch glycolate, cross-linked sodium carboxymethyl cellulose, pregelatinized starch, microcrystalline starch, water insoluble starch, calcium carboxymethyl cellulose, and low substituted hydroxypropyl cellulose magnesium aluminum silicate, or a mixture thereof.
23. The composition of claim 1 , wherein said substrate further comprises a lubricant.
24. The composition of claim 23 , wherein said lubricant is selected from the group consisting of sodium stearyl fumarate, polyethylene glycol, silica colloidal anhydrous and magnesium stearate, or a mixture thereof.
25. The composition of claim 1 , wherein said substrate further comprises an alkalinizing agent.
26. The composition of claim 25 , wherein said alkalinizing agent is selected from the group consisting of sodium stearate, meglumine, disodium phosphate, and ammonia, or a mixture thereof.
27. The composition of claim 1 , wherein said coating layer further comprises a plasticizer.
28. The composition of claim 24 , wherein said plasticizer is selected from the group consisting of a citric acid ester and a phthalic acid ester.
29. The composition of claim 1 , wherein said coating layer further comprises a surfactant.
30. The composition of claim 29 , wherein said surfactant is selected from the group consisting of polysorbate 80 and sodium lauryl sulfate.
31. The composition of claim 1 , wherein said coating layer further comprises a glidant.
32. The composition of claim 31 , wherein said glidant is selected from the group consisting of talc and titanium dioxide.
33. The composition of claim 1 , wherein said coating layer further comprises at least one of a coloring agent and a polishing agent.
34. A method for preparing a stable composition for a benzimidazole derivative, comprising:
neutralizing one or more enteric polymers to a pH of at least 6.5 with at least one volatile alkalizing agent; and
layering said one or more enteric polymers over a substrate comprising the benzimidazole derivative to form a coating layer, the composition comprising said substrate and said coating layer, such that the composition comprises less than 1000 parts per million of residual volatile alkalizing agents relative to composition weight.
35. The method of claim 34 , wherein said at least one alkalizing agent comprises one or more of amino alcohols, alkylene diamines, arginine, lysine, and ammonia solution.
36. A method for preparing a stable composition for a benzimidazole derivative, comprising:
Dissolving one or more enteric polymers in an organic solvent;
neutralizing said one or more enteric polymers to a pH of at least 6.5 with at least one volatile alkalizing agent; and
layering said one or more enteric polymers over a substrate comprising the benzimidazole derivative to form a coating layer, the composition comprising said substrate and said coating layer, such that the composition comprises less than 1000 parts per million of residual solvent relative to composition weight.
37. The method of claim 36 , wherein said neutralizing said one or more enteric coating layers comprises forming an enteric polymer suspension having a pH value of at least about 6.5.
38. The method of claim 37 , wherein said pH value of said enteric polymer suspension is from about 7 to about 10.
39. The method of claim 1 , wherein said pH is in the range of from about 7 to about 10.
40. A stable composition for a benzimidazole derivative, the composition comprising:
a substrate, said substrate comprising the benzimidazole derivative; and
a single coating layer consisting essentially of at least one neutralized enteric polymer, wherein said enteric polymer is neutralized to a pH of at least 6.5 by at least two alkalizing agents prior to applying to said substrate, wherein at least one of said at least two alkalinizing agents is a volatile alkalinizing agent and at least one of said at least two alkalinizing agents is a non-volatile alkalinizing agent,
said single coating layer layered directly over said substrate, without an intermediate layer between said substrate and said enteric coating,
wherein said composition comprises less than about 500 parts per million of residual alkalizing agent relative to the total weight of the composition.
41. The composition of claim 40 , wherein at least one of said alkilizing agents is selected from the group consisting of amino alcohols, alkylene diamines, arginine and lysine.
42. The composition of claim 40 , wherein at least one of said alkilizing agents is ammonia.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/866,255 US20110038933A1 (en) | 2008-05-06 | 2009-05-05 | Stable benzimidazole formulation |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7155708P | 2008-05-06 | 2008-05-06 | |
US12/866,255 US20110038933A1 (en) | 2008-05-06 | 2009-05-05 | Stable benzimidazole formulation |
PCT/IL2009/000467 WO2009136398A2 (en) | 2008-05-06 | 2009-05-05 | Stable benzimidazole formulation |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IL2009/000467 A-371-Of-International WO2009136398A2 (en) | 2008-05-06 | 2009-05-05 | Stable benzimidazole formulation |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/053,611 Continuation US20140178469A1 (en) | 2008-05-06 | 2013-10-15 | Stable benzimidazole formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
US20110038933A1 true US20110038933A1 (en) | 2011-02-17 |
Family
ID=41110802
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/866,255 Abandoned US20110038933A1 (en) | 2008-05-06 | 2009-05-05 | Stable benzimidazole formulation |
US14/053,611 Abandoned US20140178469A1 (en) | 2008-05-06 | 2013-10-15 | Stable benzimidazole formulation |
US15/724,502 Abandoned US20180271790A1 (en) | 2008-05-06 | 2017-10-04 | Stable benzimidazole formulation |
US17/501,237 Pending US20220031622A1 (en) | 2008-05-06 | 2021-10-14 | Stable benzimidazole formulation |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/053,611 Abandoned US20140178469A1 (en) | 2008-05-06 | 2013-10-15 | Stable benzimidazole formulation |
US15/724,502 Abandoned US20180271790A1 (en) | 2008-05-06 | 2017-10-04 | Stable benzimidazole formulation |
US17/501,237 Pending US20220031622A1 (en) | 2008-05-06 | 2021-10-14 | Stable benzimidazole formulation |
Country Status (5)
Country | Link |
---|---|
US (4) | US20110038933A1 (en) |
EP (1) | EP2293782B1 (en) |
ES (1) | ES2552723T3 (en) |
HK (1) | HK1156209A1 (en) |
WO (1) | WO2009136398A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
CN106821995B (en) * | 2017-02-22 | 2020-08-21 | 佛山市南海东方澳龙制药有限公司 | Triclabendazole preparation and preparation method and application thereof |
CN110982304B (en) * | 2019-12-06 | 2021-05-11 | 中信钛业股份有限公司 | Preparation method of titanium dioxide pigment with high resistivity |
Citations (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4148871A (en) * | 1977-10-11 | 1979-04-10 | Pitt Colin G | Sustained subdermal delivery ofdrugs using poly(ε-caprolactone) and its copolymers |
US5045321A (en) * | 1986-02-13 | 1991-09-03 | Takeda Chemical Industries, Ltd. | Stabilized pharmaceutical composition and its production |
US5225202A (en) * | 1991-09-30 | 1993-07-06 | E. R. Squibb & Sons, Inc. | Enteric coated pharmaceutical compositions |
US5433959A (en) * | 1986-02-13 | 1995-07-18 | Takeda Chemical Industries, Ltd. | Stabilized pharmaceutical composition |
US5508276A (en) * | 1994-07-18 | 1996-04-16 | Eli Lilly And Company | Duloxetine enteric pellets |
US5690960A (en) * | 1993-07-09 | 1997-11-25 | Astra Aktiebolag | Pharmaceutical formulation of omeprazole |
US5817338A (en) * | 1994-07-08 | 1998-10-06 | Astra Aktiebolag | Multiple unit tableted dosage form of omeprazole |
US6013281A (en) * | 1995-02-09 | 2000-01-11 | Astra Aktiebolag | Method of making a pharmaceutical dosage form comprising a proton pump inhibitor |
US6077541A (en) * | 1997-11-14 | 2000-06-20 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US6149942A (en) * | 1995-05-24 | 2000-11-21 | Melpha Ag | Pharmaceutical pellet formulation |
US6174548B1 (en) * | 1998-08-28 | 2001-01-16 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US6228400B1 (en) * | 1999-09-28 | 2001-05-08 | Carlsbad Technology, Inc. | Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same |
US6245351B1 (en) * | 1996-03-07 | 2001-06-12 | Takeda Chemical Industries, Ltd. | Controlled-release composition |
US6262085B1 (en) * | 1999-08-26 | 2001-07-17 | Robert R. Whittle | Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
US6268385B1 (en) * | 1999-08-26 | 2001-07-31 | Robert R. Whittle | Dry blend pharmaceutical formulations |
US6326384B1 (en) * | 1999-08-26 | 2001-12-04 | Robert R. Whittle | Dry blend pharmaceutical unit dosage form |
US20020039597A1 (en) * | 1998-04-20 | 2002-04-04 | Koji Ukai | Stabilized compositions containing benzimidazole-type compounds |
US20020054913A1 (en) * | 1996-06-28 | 2002-05-09 | Gerd-Ulfert Heese | Stable drug from for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof |
US20020098242A1 (en) * | 1997-07-31 | 2002-07-25 | Darder Carlos Picornell | Oral pharmaceutical preparation comprising an antiulcer activity compound, and process for its production |
US20020128293A1 (en) * | 1998-05-28 | 2002-09-12 | Ashok Rampal | Stable oral pharmaceutical composition containing omeprazole |
US20020160046A1 (en) * | 2000-11-29 | 2002-10-31 | Robinson Joseph R. | Delivery system for omeprazole and its salts |
US20030091643A1 (en) * | 2001-06-22 | 2003-05-15 | Friesen Dwayne T. | Pharmaceutical compositions of dispersions of drugs and neutral polymers |
US6602522B1 (en) * | 1997-11-14 | 2003-08-05 | Andrx Pharmaceuticals L.L.C. | Pharmaceutical formulation for acid-labile compounds |
US20030175348A1 (en) * | 1997-07-14 | 2003-09-18 | Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. | Novel pharmaceutical formulation with controlled release of active substances |
US20030228363A1 (en) * | 2002-06-07 | 2003-12-11 | Patel Mahendra R. | Stabilized pharmaceutical compositons containing benzimidazole compounds |
US20040028737A1 (en) * | 2002-08-12 | 2004-02-12 | Kopran Research Laboratories Limited | Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same |
US6699885B2 (en) * | 1996-01-04 | 2004-03-02 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and methods of using same |
US6726927B2 (en) * | 1997-05-09 | 2004-04-27 | Sage Pharmaceuticals, Inc. | Preparation of enteric pharmaceutical dosage forms for omerprazole and lansoprazole |
US6733778B1 (en) * | 1999-08-27 | 2004-05-11 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US6749864B2 (en) * | 1986-02-13 | 2004-06-15 | Takeda Chemical Industries, Ltd. | Stabilized pharmaceutical composition |
WO2004089333A2 (en) * | 2003-02-28 | 2004-10-21 | Cadila Healthcare Limited | A stable benzimidazole formulation |
US20040213847A1 (en) * | 2003-04-23 | 2004-10-28 | Matharu Amol Singh | Delayed release pharmaceutical compositions containing proton pump inhibitors |
US20050163846A1 (en) * | 2001-11-21 | 2005-07-28 | Eisai Co., Ltd. | Preparation composition containing acid-unstable physiologically active compound, and process for producing same |
US20070196485A1 (en) * | 1999-06-22 | 2007-08-23 | Dexcel Ltd. | Stable benzimidazole formulation |
US20100297226A1 (en) * | 2006-06-01 | 2010-11-25 | Dexcel Pharma Technologies Ltd. | Multiple unit pharmaceutical formulation |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3634271A (en) * | 1967-11-02 | 1972-01-11 | Allied Chem | Liquid detergent compositions |
EP0462723A1 (en) * | 1990-06-19 | 1991-12-27 | BP Chemicals Limited | Easily soluble granules containing a binding agent |
AU1671799A (en) * | 1997-11-28 | 1999-06-16 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Medicament preparation in the form of a tablet or pellet for acid-labile active substances |
US20030021844A1 (en) * | 1998-03-04 | 2003-01-30 | Philippe Barthelemy | Immediate-release oral pellet comprising polyglycolysed glycerides, and manufacturing process |
KR100675809B1 (en) * | 1999-07-09 | 2007-02-01 | 오르토-맥네일 파마슈티칼, 인코퍼레이티드 | Taste masked pharmaceutical liquid formulations |
KR20040011549A (en) * | 2001-06-22 | 2004-02-05 | 화이자 프로덕츠 인크. | Pharmaceutical Compositions Comprising Low-Solubility and/or Acid-Sensitive Drugs and Neutralized Acidic Polymers |
SI21402A (en) * | 2003-02-12 | 2004-08-31 | LEK farmacevtska dru�ba d.d. | Lined particles and pharmaceutical forms |
AU2004287373A1 (en) * | 2003-10-31 | 2005-05-19 | Dexcel Ltd. | Stable lansoprazole formulation |
WO2006014427A1 (en) * | 2004-07-02 | 2006-02-09 | Advancis Pharmaceutical Corporation | Tablet for pulsed delivery |
EP1830822A1 (en) * | 2004-12-24 | 2007-09-12 | LEK Pharmaceuticals D.D. | Stable pharmaceutical composition comprising an active substance in the form of solid solution |
WO2006129386A1 (en) * | 2005-06-03 | 2006-12-07 | Medrx Co., Ltd. | Enteric medicinal composition for oral use |
GB0519391D0 (en) * | 2005-09-22 | 2005-11-02 | Aion Diagnostics Ltd | Imaging agents |
US20070243252A1 (en) * | 2006-04-17 | 2007-10-18 | Actavis Group Ptc Hf | Oral Dosage Formulations and Methods of Preparing the Same |
US20090175935A1 (en) * | 2006-08-14 | 2009-07-09 | Torrent Research Ltd. | Pharmaceutical compositions of duloxetine |
-
2009
- 2009-05-05 EP EP09742569.8A patent/EP2293782B1/en active Active
- 2009-05-05 ES ES09742569.8T patent/ES2552723T3/en active Active
- 2009-05-05 US US12/866,255 patent/US20110038933A1/en not_active Abandoned
- 2009-05-05 WO PCT/IL2009/000467 patent/WO2009136398A2/en active Application Filing
-
2011
- 2011-09-15 HK HK11109701.8A patent/HK1156209A1/en unknown
-
2013
- 2013-10-15 US US14/053,611 patent/US20140178469A1/en not_active Abandoned
-
2017
- 2017-10-04 US US15/724,502 patent/US20180271790A1/en not_active Abandoned
-
2021
- 2021-10-14 US US17/501,237 patent/US20220031622A1/en active Pending
Patent Citations (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4148871A (en) * | 1977-10-11 | 1979-04-10 | Pitt Colin G | Sustained subdermal delivery ofdrugs using poly(ε-caprolactone) and its copolymers |
US5639478A (en) * | 1986-02-13 | 1997-06-17 | Takeda Chemical Industries, Ltd. | Method to stabilize a pharmaceutical composition and its production |
US5093132A (en) * | 1986-02-13 | 1992-03-03 | Takeda Chemical Industries, Ltd. | Stabilized pharmaceutical composition and its production |
US20040209919A1 (en) * | 1986-02-13 | 2004-10-21 | Takeda Chemical Industries, Ltd. | Stabilized pharmaceutical composition |
US5433959A (en) * | 1986-02-13 | 1995-07-18 | Takeda Chemical Industries, Ltd. | Stabilized pharmaceutical composition |
US6123962A (en) * | 1986-02-13 | 2000-09-26 | Takeda Chemical Industries, Inc. | Process for producing stabilized pharmaceutical composition |
US6380234B1 (en) * | 1986-02-13 | 2002-04-30 | Takeda Chemical Industries, Ltd. | Stabilized pharmaceutical composition and its production |
US6296875B1 (en) * | 1986-02-13 | 2001-10-02 | Takeda Chemical Industries, Ltd. | Method for producing a granule |
US6749864B2 (en) * | 1986-02-13 | 2004-06-15 | Takeda Chemical Industries, Ltd. | Stabilized pharmaceutical composition |
US5879708A (en) * | 1986-02-13 | 1999-03-09 | Takeda Chemical Industries, Ltd. | Stabilized pharmaceutical composition |
US6521256B2 (en) * | 1986-02-13 | 2003-02-18 | Takeda Chemical Industries, Ltd. | Stabilized pharmaceutical composition |
US6017560A (en) * | 1986-02-13 | 2000-01-25 | Takeda Chemical Industries, Ltd. | Process for producing stabilized pharmaceutical composition |
US5045321A (en) * | 1986-02-13 | 1991-09-03 | Takeda Chemical Industries, Ltd. | Stabilized pharmaceutical composition and its production |
US5225202A (en) * | 1991-09-30 | 1993-07-06 | E. R. Squibb & Sons, Inc. | Enteric coated pharmaceutical compositions |
US5690960A (en) * | 1993-07-09 | 1997-11-25 | Astra Aktiebolag | Pharmaceutical formulation of omeprazole |
US5817338A (en) * | 1994-07-08 | 1998-10-06 | Astra Aktiebolag | Multiple unit tableted dosage form of omeprazole |
US5508276A (en) * | 1994-07-18 | 1996-04-16 | Eli Lilly And Company | Duloxetine enteric pellets |
US6013281A (en) * | 1995-02-09 | 2000-01-11 | Astra Aktiebolag | Method of making a pharmaceutical dosage form comprising a proton pump inhibitor |
US6149942A (en) * | 1995-05-24 | 2000-11-21 | Melpha Ag | Pharmaceutical pellet formulation |
US6699885B2 (en) * | 1996-01-04 | 2004-03-02 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and methods of using same |
US6245351B1 (en) * | 1996-03-07 | 2001-06-12 | Takeda Chemical Industries, Ltd. | Controlled-release composition |
US6623759B2 (en) * | 1996-06-28 | 2003-09-23 | Astrazeneca Ab | Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof |
US20020054913A1 (en) * | 1996-06-28 | 2002-05-09 | Gerd-Ulfert Heese | Stable drug from for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof |
US6726927B2 (en) * | 1997-05-09 | 2004-04-27 | Sage Pharmaceuticals, Inc. | Preparation of enteric pharmaceutical dosage forms for omerprazole and lansoprazole |
US20030175348A1 (en) * | 1997-07-14 | 2003-09-18 | Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. | Novel pharmaceutical formulation with controlled release of active substances |
US20020098242A1 (en) * | 1997-07-31 | 2002-07-25 | Darder Carlos Picornell | Oral pharmaceutical preparation comprising an antiulcer activity compound, and process for its production |
US6077541A (en) * | 1997-11-14 | 2000-06-20 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US6602522B1 (en) * | 1997-11-14 | 2003-08-05 | Andrx Pharmaceuticals L.L.C. | Pharmaceutical formulation for acid-labile compounds |
US6096340A (en) * | 1997-11-14 | 2000-08-01 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US6780435B2 (en) * | 1997-11-14 | 2004-08-24 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US20020039597A1 (en) * | 1998-04-20 | 2002-04-04 | Koji Ukai | Stabilized compositions containing benzimidazole-type compounds |
US20020128293A1 (en) * | 1998-05-28 | 2002-09-12 | Ashok Rampal | Stable oral pharmaceutical composition containing omeprazole |
US6174548B1 (en) * | 1998-08-28 | 2001-01-16 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US6855336B2 (en) * | 1998-08-28 | 2005-02-15 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US20040175427A1 (en) * | 1998-08-28 | 2004-09-09 | Chih-Ming Chen | Omeprazole formulation |
US20070196485A1 (en) * | 1999-06-22 | 2007-08-23 | Dexcel Ltd. | Stable benzimidazole formulation |
US6326384B1 (en) * | 1999-08-26 | 2001-12-04 | Robert R. Whittle | Dry blend pharmaceutical unit dosage form |
US6268385B1 (en) * | 1999-08-26 | 2001-07-31 | Robert R. Whittle | Dry blend pharmaceutical formulations |
US6262085B1 (en) * | 1999-08-26 | 2001-07-17 | Robert R. Whittle | Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
US6733778B1 (en) * | 1999-08-27 | 2004-05-11 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US6228400B1 (en) * | 1999-09-28 | 2001-05-08 | Carlsbad Technology, Inc. | Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same |
US20020160046A1 (en) * | 2000-11-29 | 2002-10-31 | Robinson Joseph R. | Delivery system for omeprazole and its salts |
US20030091643A1 (en) * | 2001-06-22 | 2003-05-15 | Friesen Dwayne T. | Pharmaceutical compositions of dispersions of drugs and neutral polymers |
US20050163846A1 (en) * | 2001-11-21 | 2005-07-28 | Eisai Co., Ltd. | Preparation composition containing acid-unstable physiologically active compound, and process for producing same |
US20030228363A1 (en) * | 2002-06-07 | 2003-12-11 | Patel Mahendra R. | Stabilized pharmaceutical compositons containing benzimidazole compounds |
US20030236285A1 (en) * | 2002-06-07 | 2003-12-25 | Patel Mahendra R. | Stabilized pharmaceutical compositions containing benzimidazole compounds |
US20040028737A1 (en) * | 2002-08-12 | 2004-02-12 | Kopran Research Laboratories Limited | Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same |
WO2004089333A2 (en) * | 2003-02-28 | 2004-10-21 | Cadila Healthcare Limited | A stable benzimidazole formulation |
US20040213847A1 (en) * | 2003-04-23 | 2004-10-28 | Matharu Amol Singh | Delayed release pharmaceutical compositions containing proton pump inhibitors |
US20100297226A1 (en) * | 2006-06-01 | 2010-11-25 | Dexcel Pharma Technologies Ltd. | Multiple unit pharmaceutical formulation |
Also Published As
Publication number | Publication date |
---|---|
US20220031622A1 (en) | 2022-02-03 |
ES2552723T3 (en) | 2015-12-01 |
US20180271790A1 (en) | 2018-09-27 |
WO2009136398A2 (en) | 2009-11-12 |
EP2293782A2 (en) | 2011-03-16 |
WO2009136398A3 (en) | 2009-12-23 |
HK1156209A1 (en) | 2012-06-08 |
EP2293782B1 (en) | 2015-08-12 |
US20140178469A1 (en) | 2014-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220031622A1 (en) | Stable benzimidazole formulation | |
EP2645996B1 (en) | Method for producing a pharmaceutical composition comprising proton pump inhibitors | |
US9023391B2 (en) | Stable benzimidazole formulation | |
US6428810B1 (en) | Pharmaceutical formulation comprising omeprazole | |
KR100540721B1 (en) | Pharmaceutical Formulation of Omeprazole | |
US20070065513A1 (en) | Stable lansoprazole formulation | |
US20050214371A1 (en) | Stable pharmaceutical composition comprising an acid labile drug | |
CA2637444C (en) | Coated pharmaceutical composition of tolterodine or a salt thereof having rapid dissolution at acidic conditions and slow dissolution at higher ph values | |
US20020128293A1 (en) | Stable oral pharmaceutical composition containing omeprazole | |
JP2000514051A (en) | Stable pharmaceutical form for oral administration containing benzimidazole derivative as active ingredient and method for producing the same | |
US20130216617A1 (en) | Pharmaceutical compositions of (r)-lansoprazole | |
EP2773348B1 (en) | Pharmaceutical composition of omeprazole | |
US20120231074A1 (en) | Pharmaceutical solid dosage form | |
US10835488B2 (en) | Stable orally disintegrating pharmaceutical compositions | |
EP2345408A2 (en) | Acid labile drug formulations | |
US20210369695A1 (en) | Pharmaceutical composition containing dabigatran etexilate and preparation method thereof | |
US20030236285A1 (en) | Stabilized pharmaceutical compositions containing benzimidazole compounds | |
WO2003103638A1 (en) | Stabilized pharmaceutical compositions containing benzimidazole compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: DEXCEL PHARMA TECHNOLOGIES LTD., ISRAEL Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GOMBERG, MAXIM;PENHASI, ADEL;AVRAMOFF, AVI;AND OTHERS;REEL/FRAME:025615/0188 Effective date: 20100609 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |